百济神州(06160.HK)预计下半年公布欧司珀利单抗1期试验扩展队列数据

美港电讯2022-06-17

美港电讯APP 6月17日讯，百济神州6月16日披露的投资者关系活动记录表显示，其在5月13日机构调研时表示，公司会根据外部和内部的临床试验数据陆续读出进一步评估开发策略。公司在推进在研TIGIT项目欧司珀利单抗进入三期试验前对内部早期实验结果以及罗氏汇报的结果进行了详细的分析，认为自研TIGIT项目仍然具备潜力。公司预计今年下半年公布欧司珀利单抗1期试验扩展队列的数据。（界面新闻）

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

大伟大伟
2022-06-17
大伟大伟
分红才是硬道理

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2244193298?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-06-17 14:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2244193298","market":"hk","top_or_hot":-1,"title":"百济神州(06160.HK)预计下半年公布欧司珀利单抗1期试验扩展队列数据","media":"美港电讯","content":"<div>\n<p>美港电讯APP 6月17日讯，百济神州6月16日披露的投资者关系活动记录表显示，其在5月13日机构调研时表示，公司会根据外部和内部的临床试验数据陆续读出进一步评估开发策略。公司在推进在研TIGIT项目欧司珀利单抗进入三期试验前对内部早期实验结果以及罗氏汇报的结果进行了详细的分析，认为自研TIGIT项目仍然具备潜力。公司预计今年下半年公布欧司珀利单抗1期试验扩展队列的数据。（界面新闻）</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220617142802804a9902&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州(06160.HK)预计下半年公布欧司珀利单抗1期试验扩展队列数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州(06160.HK)预计下半年公布欧司珀利单抗1期试验扩展队列数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-17 14:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220617142802804a9902&s=b><strong>美港电讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美港电讯APP 6月17日讯，百济神州6月16日披露的投资者关系活动记录表显示，其在5月13日机构调研时表示，公司会根据外部和内部的临床试验数据陆续读出进一步评估开发策略。公司在推进在研TIGIT项目欧司珀利单抗进入三期试验前对内部早期实验结果以及罗氏汇报的结果进行了详细的分析，认为自研TIGIT项目仍然具备潜力。公司预计今年下半年公布欧司珀利单抗1期试验扩展队列的数据。（界面新闻）</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220617142802804a9902&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220617142802804a9902&s=b","article_id":"2244193298","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220617142802804a9902&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2244193298","pubTimestamp":1655447266,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"美港电讯APP 6月17日讯，百济神州6月16日披露的投资者关系活动记录表显示，其在5月13日机构调研时表示，公司会根据外部和内部的临床试验数据陆续读出进一步评估开发策略。公司在推进在研TIGIT项目欧司珀利单抗进入三期试验前对内部早期实验结果以及罗氏汇报的结果进行了详细的分析，认为自研TIGIT项目仍然具备潜力。公司预计今年下半年公布欧司珀利单抗1期试验扩展队列的数据。（界面新闻）","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1588":"回港中概股","06160":"百济神州","BK1500":"做空集合股","BK1161":"生物科技","BK1583":"高瓴概念"},"translate_title":"Baekje Shenzhou (06160. HK) is expected to announce the expanded cohort data of Oselizumab Phase 1 trial in the second half of the year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":0.9},"content_text":"美港电讯APP 6月17日讯，百济神州6月16日披露的投资者关系活动记录表显示，其在5月13日机构调研时表示，公司会根据外部和内部的临床试验数据陆续读出进一步评估开发策略。公司在推进在研TIGIT项目欧司珀利单抗进入三期试验前对内部早期实验结果以及罗氏汇报的结果进行了详细的分析，认为自研TIGIT项目仍然具备潜力。公司预计今年下半年公布欧司珀利单抗1期试验扩展队列的数据。（界面新闻）","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[{"id":689897752,"gmtCreate":1655454129592,"gmtModify":1704862442082,"author":{"id":"3526692614202261","authorId":"3526692614202261","name":"大伟大伟","avatar":"https://static.tigerbbs.com/04a3ce61112d4c0ec3f5d6d97f3f6475","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"分红才是硬道理","listText":"分红才是硬道理","text":"分红才是硬道理","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/689897752","repostId":2244193298,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2244193298"}